Peri-procedural Anticoagulation and the Incidence of Haematoma Formation after Permanent Pacemaker Implantation in the Elderly

Heart Lung and Circulation

Volumn 19, Issue 12, 2010, Pages 706-712

  Chow, Vincent ^a   Ranasinghe, Isuru ^a   Lau, Jerrett ^a   Stowe, Hughina ^a   Bannon, Paul ^b   Hendel, Nick ^b   Kritharides, Leonard ^a  

^a Department of Microbiology and Infectious Diseases   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

Anticoagulation; Complication; Haematoma; Pacemaker

Indexed keywords

ANTIBIOTIC AGENT; ENOXAPARIN; WARFARIN;

AGED; ANTIBIOTIC PROPHYLAXIS; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; ARTIFICIAL HEART PACEMAKER; ATRIOVENTRICULAR BLOCK; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEMATOMA; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; OUTCOME ASSESSMENT; POSTOPERATIVE INFECTION; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; THROMBOEMBOLISM; TREATMENT INDICATION;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; CARDIAC SURGICAL PROCEDURES; FEMALE; HEMATOMA; HEPARIN; HUMANS; INCIDENCE; LENGTH OF STAY; MALE; MULTIVARIATE ANALYSIS; PACEMAKER, ARTIFICIAL; PERIOPERATIVE PERIOD; RETROSPECTIVE STUDIES; RISK FACTORS; WARFARIN;

EID: 78149466367     PISSN: 14439506     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hlc.2010.08.011     Document Type: Article

References (22)

1. Mond H.G., Whitlock R.M.L. The Australian and New Zealand cardiac pacing and implantable cardioverter-defibrillator survey: calendar year 2005. Heart Lung Circ 2008, 17(2 (April)):85-89.
2. Zhan C., Baine W.B., Sedrakyan A., Steiner C. Cardiac device implantation in the United States from 1997 through 2004: a population-based analysis. J Gen Intern Med 2008, 23(Suppl. 1 (January)):13-19.
3. Eberhardt F., Bode F., Bonnemeier H., Boguschewski F., Schlei M., Peters W., et al. Long term complications in single and dual chamber pacing are influenced by surgical experience and patient morbidity. Heart 2005, 91(4 (April)):500-506.
4. Ellenbogen K.A., Hellkamp A.S., Wilkoff B.L., Camunas J.L., Love J.C., Hadjis T.A., et al. Complications arising after implantation of DDD pacemakers: the MOST experience. Am J Cardiol 2003, 92(6 (September 15)):740-741.
5. Moller M., Arnsbo P., Asklund M., Christensen P.D., Gadsboll N., Svendsen J.H., et al. Quality assessment of pacemaker implantations in Denmark. Europace 2002, 4(2 (April)):107-112.
6. van Eck J.W., van Hemel N.M., Zuithof P., van Asseldonk J.P., Voskuil T.L., Grobbee D.E., et al. Incidence and predictors of in-hospital events after first implantation of pacemakers. Europace 2007, 9(10 (October)):884-889.
7. Clinical Excellence Commission (CEC). Review of implantation procedures for permanent pacemakers in NSW Public Hospitals - 2007, Scientific report. Sydney: CEC2007; 2007.
8. Tompkins C., Cheng A., Dalal D., Brinker J.A., Leng C.T., Marine J.E., et al. Dual antiplatelet therapy and heparin "bridging" significantly increase the risk of bleeding complications after pacemaker or implantable cardioverter-defibrillator device implantation. J Am Coll Cardiol 2010, 55(21 (May 25)):2376-2382.
9. Choo M.H., Holmes D.R., Gersh B.J., Maloney J.D., Merideth J., Pluth J.R., et al. Permanent pacemaker infections: characterization and management. Am J Cardiol 1981, 48(3 (September)):559-564.
10. Bailey S.M., Wilkoff B.L. Complications of pacemakers and defibrillators in the elderly. Am J Geriatr Cardiol 2006, 15(2 (March-April)):102-107.
11. Marquie C., De Geeter G., Klug D., Kouakam C., Brigadeau F., Jabourek O., et al. Post-operative use of heparin increases morbidity of pacemaker implantation. Europace 2006, 8(4 (April)):283-287.
12. Michaud G.F., Pelosi F., Noble M.D., Knight B.P., Morady F., Strickberger S.A. A randomized trial comparing heparin initiation 6h or 24h after pacemaker or defibrillator implantation. J Am Coll Cardiol 2000, 35(7 (June)):1915-1918.
13. Wiegand U.K., LeJeune D., Boguschewski F., Bonnemeier H., Eberhardt F., Schunkert H., et al. Pocket hematoma after pacemaker or implantable cardioverter defibrillator surgery: influence of patient morbidity, operation strategy, and perioperative antiplatelet/anticoagulation therapy. Chest 2004, 126(4 (October)):1177-1186.
14. Kaplan R.C., Tirschwell D.L., Longstreth W.T., Manolio T.A., Heckbert S.R., Lefkowitz D., et al. Vascular events, mortality, and preventive therapy following ischemic stroke in the elderly. Neurology 2005, 65(6 (September 27)):835-842.
15. Jamula E., Douketis J.D., Schulman S. Perioperative anticoagulation in patients having implantation of a cardiac pacemaker or defibrillator: a systematic review and practical management guide. J Thromb Haemost 2008, 6(10 (October)):1615-1621.
16. Bonow R.O., Carabello B.A., Chatterjee K., de Leon A.C., Faxon D.P., Freed M.D., et al. 2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1998 guidelines for the management of patients with valvular heart disease). Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2008, 52(13 (September 23)):e1-e142.
17. Cannegieter S.C., Rosendaal F.R., Briet E. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation 1994, 89(2 (February)):635-641.
18. Baudet E.M., Oca C.C., Roques X.F., Laborde M.N., Hafez A.S., Collot M.A., et al. A 5 1/2 year experience with the St. Jude Medical cardiac valve prosthesis. Early and late results of 737 valve replacements in 671 patients. J Thorac Cardiovasc Surg 1985, 90(1 (July)):137-144.
19. Tolosana J.M., Berne P., Mont L., Heras M., Berruezo A., Monteagudo J., et al. Preparation for pacemaker or implantable cardiac defibrillator implants in patients with high risk of thrombo-embolic events: oral anticoagulation or bridging with intravenous heparin? A prospective randomized trial. Eur Heart J 2009, 30(15 (August)):1880-1884.
20. Fuster V., Ryden L.E., Cannom D.S., Crijns H.J., Curtis A.B., Ellenbogen K.A., et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation - executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol 2006, 48(4 (August 15)):854-906.
21. Gage B.F., Waterman A.D., Shannon W., Boechler M., Rich M.W., Radford M.J. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001, 285(22 (June 13)):2864-2870.
22. Agnelli G., Prandoni P., Becattini C., Silingardi M., Taliani M.R., Miccio M., et al. Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Ann Intern Med 2003, 139(1 (July 1)):19-25.